Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 6/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849868 | 0.86 | DRD2 (0.56) | DRD2HTR1ADRD3HTR2AADRA1B | |
| SCHEMBL3847035 | 0.85 | FFAR4 (0.51) | DRD2HTR1AFFAR4SLC6A2SLC6A3 | |
| SCHEMBL3847616 | 0.85 | DRD2 (0.61) | DRD2HTR1ASLC6A2DRD3HTR2A | |
| SCHEMBL3844138 | 0.85 | HTR1A (0.55) | DRD2HTR1AFFAR4SLC6A2SLC6A3 | |
| SCHEMBL3851104 | 0.84 | DRD2 (0.54) | DRD2HTR1AFFAR4DRD3HTR2A | |
| SCHEMBL3847633 | 0.82 | DRD2 (0.56) | DRD2HTR1ADRD3HTR2AADRA1B | |
| SCHEMBL4496655 | 0.81 | DRD2 (0.54) | DRD2HTR1AFFAR4DRD3HTR2A | |
| SCHEMBL13630520 | 0.81 | DRD2 (0.54) | DRD2HTR1AFFAR4DRD3HTR2A | |
| SCHEMBL3847619 | 0.81 | DRD2 (0.65) | DRD2HTR1ADRD3HTR2A | |
| SCHEMBL3853796 | 0.80 | FFAR4 (0.50) | DRD2HTR1AFFAR4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | claimed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | claimed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | claimed |
| EP-2038268-A2 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-25 | — | — | EP | claimed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | claimed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| EP-2038268-A2 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | DRD2 4/4885HTR1A 192/4885FFAR4 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.